Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 941 of 6351
-
Pedal power: could indoor cycling delay Alzheimer's in At-Risk seniors?
Prevention OngoingThe overall goal of the CYCLE-AD trial is to determine the role of long-term, high intensity exercise in slowing or delaying the onset of cognitive and AD-related brain changes in e4 carriers. Successful translation and demonstration of the effectiveness of a scalable home-based …
Sponsor: The Cleveland Clinic • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThe primary objectives of this study are as follows: Phase 1 (sequential dose-escalation): to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent and to determine the recommended Phase 2 dose (RP2D) of SG in Japanese participants with advanc…
Phase 1/2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could zapping kidney nerves tame tough high blood pressure?
Disease control OngoingThe purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects prev…
Sponsor: Medtronic Vascular • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Eye drops could replace needles for diabetic eye swelling
Disease control CompletedThe primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).
Phase 2/3 • Sponsor: Oculis • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Supercharged t cells aim to block COVID in vulnerable transplant patients
Prevention Recruiting nowThis is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor…
Phase 1 • Sponsor: Children's National Research Institute • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
Could less hormone therapy be enough for High-Risk prostate cancer?
Disease control OngoingThe purpose of this study is to find out whether combining a shorter than standard course of ADT with standard prostate brachytherapy and hypofractionated external beam radiation therapy is a safe and effective way to prevent high-risk prostate cancer from coming back and/or spre…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for kids with severe gut disease: drug shows promise in remission
Disease control CompletedVedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab. The main aim of the study is to check if participants achieve remissio…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Hair loss drug shows promise in Long-Term trial
Disease control CompletedThe overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clin…
Phase 3 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedPICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expressi…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo therapy aims to outsmart aggressive lymphoma
Disease control OngoingThis study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) requiring full course chemo…
Phase 2 • Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Peer support may shield immigrants and refugees from pandemic stress
Disease control OngoingThis study tests the effectiveness of a community-based peer advocacy, mutual learning, and social support intervention (Refugee and Immigrant Well-being Project) to reduce several negative consequences of the COVID-19 pandemic that are disproportionately impacting Latinx and Bla…
Sponsor: University of New Mexico • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis phase IB trial evaluates the effect of niraparib and TSR-042 in treating patients with BRCA-mutated breast, pancreas, ovary, fallopian tube, or primary peritoneal cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). …
Phase 1 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for certain cancers
Disease control OngoingThis trial is a multicenter, 3-cohort, prospective, Phase II trial conducted in patients with untreated resectable MSI/dMMR carcinomas and aiming to evaluate the safety and the efficacy of ICI (immune checkpoint inhibitor) as neoadjuvant treatment in these patients. We hypothesi…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a drug make milk allergy therapy safer and more effective?
Disease control Stopped earlyThis is a phase 2, multicenter, randomized, double-blind, parallel group, 2 arm study in approximately 40 subjects aged 4 to 50 years, inclusive, who are allergic to cow's milk. The primary objective is to assess whether dupilumab as an adjunct to milk oral immunotherapy (OIT) co…
Phase 2 • Sponsor: Andrew J Long, PharmD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Mom's workout may shield baby from obesity
Prevention Recruiting nowThe overall objective of this proposal is to conduct a longitudinal prospective study of overweight/obese (OW/OB) pregnant women and their offspring to determine which prenatal exercise mode will have the greatest impact on maternal and infant cardiometabolic health. This informa…
Sponsor: East Carolina University • Aim: Prevention
Last updated Jun 27, 2026 13:02 UTC
-
Booster breakthrough: mRNA shot supercharges immunity in inactivated vaccine recipients
Vaccine Completed300 adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine at least 3 months earlier will receive a third dose with an mRNA vaccine (BNT162b2, BioNTech). Investigators will monitor reactogenicity and measure the immune response to the th…
Phase 4 • Sponsor: The University of Hong Kong • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
-
Zapping kidney nerves may tame both hypertension and anxiety
Disease control CompletedThe ERSHAM (Effect of Renal Denervation on Stress, Hypertension and Anxiety Management) is a single-center, interventional, open-label, randomized controlled trial that will be conducted at the Hypertension Unit "ESH Excellence Center'', 1st Cardiology Department of the Medical S…
Phase 2 • Sponsor: Hippocration General Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
A new strategy to keep workers on the job after injury or illness
Disease control CompletedThe Retaining Employment and Talent after Injury/Illness Network (RETAIN) demonstration is a collaborative effort between the U.S. Department of Labor (DOL) and the Social Security Administration (SSA) to improve employment outcomes for individuals who experience injuries or illn…
Sponsor: Mathematica Policy Research, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Heart-Lung machine at the scene boosts cardiac arrest survival
Disease control CompletedHypothesis: Implantation of on-scene ECPR by the HEMS teams in patients with sustained out-of-hospital cardiac arrest, results in the rapid return of circulation and, thus, improved survival and less neurological impairment, which is associated with lower health care costs.
Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo shows promise in shrinking melanoma before surgery
Disease control OngoingThis phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC